<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04585698</url>
  </required_header>
  <id_info>
    <org_study_id>ULiege_CHEPS_AM_MM_JS</org_study_id>
    <nct_id>NCT04585698</nct_id>
  </id_info>
  <brief_title>QST, Blink Reflex and Nociceptive Flexion Reflex in Headache</brief_title>
  <official_title>Quantitative Sensory Testing, Blink Reflex and Nociceptive Flexion Reflex in the Pathophysiology of Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare central and peripheric sensitization in headache patients&#xD;
      at Baseline (T0) and 1 month after (T1) a treatment with an anti-CGRP (Fremanezumab-Ajovy).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      20 patients and 20 healthy subjects will be enrolled. The headache patients will be recruited&#xD;
      just before starting their treatment and 1 month after (corresponding to the efficacy peak).&#xD;
      Hot and cold stimulations will be delivered with the ATS probe from the Medoc Pathway on the&#xD;
      forehead and on the hand (palmar face) to determine painful threshold to warm/cold stimuli. A&#xD;
      blink reflex will be generated with a concentric electrode placed over the eyebrow and with&#xD;
      active/earth electrodes linked to the EMG machine for the recording. For the nociceptive&#xD;
      flexion reflex, a cutaneous stimulation will be applied on the arm and the response recorded&#xD;
      on the corresponding muscles.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>modulation of pain threshold by fremanezumab</measure>
    <time_frame>one year</time_frame>
    <description>quantitative analysis of pain-related reflexes with QST (quantitative sensory testing) using Medoc Pathway</description>
  </primary_outcome>
  <primary_outcome>
    <measure>modulation of pain threshold by fremanezumab</measure>
    <time_frame>one year</time_frame>
    <description>Blink reflex and nociceptive flexion reflex usig EMG Viking Viasys.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Head Pain</condition>
  <arm_group>
    <arm_group_label>headache patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy subjects</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with headache before and 1 month after receiving fremanezumab&#xD;
&#xD;
        Age: 18-65 years&#xD;
&#xD;
        Sex: 2/3 female, 1/3 male&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: patients with headache which are about to receive a treatment with&#xD;
        fremanezumab&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  medication changes 1 month prior to the test&#xD;
&#xD;
          -  neuropathy&#xD;
&#xD;
          -  acute or chronic pain&#xD;
&#xD;
          -  medications having effects on the central nervous system&#xD;
&#xD;
          -  other disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 12, 2020</last_update_submitted>
  <last_update_submitted_qc>October 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liege</investigator_affiliation>
    <investigator_full_name>Manise Maite</investigator_full_name>
    <investigator_title>Doctor in Medical Sciences</investigator_title>
  </responsible_party>
  <keyword>headache</keyword>
  <keyword>fremanezumab</keyword>
  <keyword>blink reflex</keyword>
  <keyword>nociceptive flexion reflex</keyword>
  <keyword>quantitative sensory testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

